List view / Grid view
The Mark Foundation for Cancer Research awards ~$12 million to Cancer Grand Challenges Team to develop new immunotherapies for childhood solid tumours.
Scientists have found a way to “supercharge” tumour-attacking T cells, which could improve the effectiveness of cell-based cancer immunotherapy and expand the number of cancers it can treat.
Scientists have developed a novel chimeric antigen receptor (CAR) T-cell therapy to target a variety of human and murine solid-tumour cancer cells.
22 April 2015 | By Victoria White
Blend Therapeutics has presented preclinical data on it's lead product candidate, BTP-114, a novel personalised cisplatin prodrug, at AACR 2015...
